0N5A Stock Chart & Stats
€1.54
€0.07(4.58%)
At close: 4:00 PM EST
€1.54
€0.07(4.58%)
Day’s Range― - ―
52-Week Range€1.35 - €2.58
Previous CloseN/A
Volume9.00
Average Volume (3M)6.00
Market Cap
€21.63M
Enterprise Value€28.81
Total Cash (Recent Filing)€1.40M
Total Debt (Recent Filing)€984.00K
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding14,716,976
10 Day Avg. Volume18
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthStrong recent revenue growth indicates improving demand for aap Implantate’s orthopedic and trauma products. Sustained top-line expansion could broaden its market presence and create operating leverage if growth continues across hospitals and distribution channels.
High Gross MarginsConsistently high gross margins suggest the company’s implants and related instruments retain meaningful product-level economics. This provides a foundation for future profitability, provided management can control operating expenses and convert gross profit into positive earnings.
Improved Balance Sheet LeverageMaterial debt reduction lowers financing risk and improves financial flexibility for a small medical technology company. A less leveraged balance sheet may support investment in product development, regulatory requirements and distribution while reducing pressure from interest obligations.
Bears Say
Persistent Operating LossesOngoing operating and net losses show that revenue growth and strong gross margins have not yet translated into a viable earnings model. If this persists, the company may face continued funding needs and limited capacity to reinvest in commercial expansion.
Sustained Cash BurnPersistent negative operating and free cash flow indicates the business is not self-funding despite recent revenue improvement. Continued cash burn can constrain product development and market expansion, while increasing reliance on financing or other liquidity sources.
Negative Returns On EquityNegative returns on equity indicate that the company has not yet generated economic returns for shareholders from its capital base. Unless profitability improves, recurring losses could erode equity over time and reduce long-term financial resilience.
0N5A FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest share price was €1.35 and its highest was €2.58 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €21.63M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 18, 2027 which is in 355 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Aug 17, 2026. The company reported -€0.078 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.078 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in GB:0N5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.18%
Trailing 12-Months
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―